Webe Honey – Lifestyle
Home
Sample Page
Author:
Theolytics
Theolytics Announces First Patient Dosed in the OCTOPOD-IP Trial, a US Phase 1 Trial with THEO-260, a Novel Oncolytic Immunotherapy Targeting Ovarian Cancer
April 28, 2026